Patent · US Expired

Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity

US7189723B2 · kind B2 · utility

43Cited by
4References
35Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 10, 2004
Grant dateMar 13, 2007
Priority date
Expiry dateNov 7, 2024

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P37/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention pertains to compounds of Formula I:and all pharmaceutically-acceptable forms thereof.The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein.The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents.The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound or salt of the invention to decrease the symptoms or slow the progression of these diseases or disorders.The invention also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an disease or disorder responsive…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.